Condition

Inflammatory Myofibroblastic Tumor (3)

Anaplastic Large Cell Lymphoma (1)

Anaplastic Large Cell Lymphoma, ALK-Positive (1)

Glioblastoma (1)

Other Solid Tumor (1)

Tumors With Aberrations in ALK (1)

Overall Status

Recruiting (1)

Terminated (1)

Unknown status (1)

Sign in for free

Phase

phase 1/phase 2 (1)

phase 2 (1)

phase 2/phase 3 (1)

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1)

Novartis Pharmaceuticals (1)

Princess Maxima Center for Pediatric Oncology (1)

Collaborator

Takeda (1)

Intervention

brigatinib (1)

ceritinib (ldk378) (1)

crizotinib (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

inflammatory myofibroblastic tumor

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting

Anaplastic Large Cell Lymphoma, ALK-Positive
+2 more

Brigatinib

Paris, France
+1 more

Sep 27, 2022

Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor Trial in Worldwide (Ceritinib

Terminated

Tumors With Aberrations in ALK
+3 more

Ceritinib (LDK378)

Brno, Czech Republic, Czechia
+13 more

Dec 17, 2019

Inflammatory Myofibroblastic Tumor Trial in Moscow (Crizotinib)

Unknown status

Inflammatory Myofibroblastic Tumor

Crizotinib

Moscow, Russian Federation

Dmitry Rogachev National Research Center of Pediatric Hematology

Mar 13, 2019